Download PDF
Semin Respir Crit Care Med 2007; 28(2): 159-170
DOI: 10.1055/s-2007-976488
Copyright © 2007 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Pandemic (Avian) Influenza

Sumanth Rajagopal1 , John Treanor1
  • 1Department of Medicine, Infectious Diseases Division, University of Rochester School of Medicine and Dentistry, Rochester, New York
Further Information

Publication History

Publication Date:
25 April 2007 (online)

    Permissions and Reprints

ABSTRACT

Pandemics of influenza have been reported since the early sixteenth century. Recent pandemics include the Spanish flu (H1N1) from 1918 to 1920 (resulting in ~50 million deaths worldwide); the Asian flu (H2N2) from 1957 to 1958 (resulting in more than 1 million deaths); the Hong Kong flu (H3N2) from 1968 to 1970 (responsible for approximately 700,000 deaths). Avian influenza viruses have now been identified as a source of novel hemagglutinin (HA) and neuraminidases (NAs) associated with pandemics. Although infections in humans with avian strains are uncommon, several outbreaks of severe influenza with highly virulent H5N1 strains derived from infected poultry were reported in China and other Asian countries since 2003. Large-scale culling operations and intensified surveillance led to eradication of H5N1 infection in poultry in some countries, but H5N1 infection in wild birds and domestic poultry has become endemic in many countries. The potential exists for global pandemics of unprecedented magnitude. In this review, we discuss the epidemiology and genetics of avian influenza viruses, the potential for transmission of disease to humans, clinical features of avian influenza infections in humans, appropriate diagnostic testing, and treatment. We also discuss global efforts for disease prevention via a host of programs, including intensified surveillance, culling of infected birds, education of medical personnel and the public, production of vaccines, and use of specific antiviral agents (e.g., adamantanes and neuraminidase inhibitors).

KEYWORDS

Avian influenza - pandemic influenza - H5N1 influenza A virus - human influenza virus

REFERENCES

  • 1 World Bank .http://Avian Flu: The Economic Costs: www.worldbank.org/avianflu
  • 2 Nicholson K G, Webster R G, Hay A J. Textbook of Influenza. London, UK; Blackwell Science Ltd 1998
    Google Scholar
  • 3 Johnson N P, Mueller J. Updating the accounts: global mortality of the 1918-1920 “Spanish” influenza pandemic.  Bull Hist Med. 2002;  76 105-115
    CrossrefPubMedGoogle Scholar
  • 4 Crosby W. America's Forgotten Pandemic: Influenza of 1918. Cambridge; Cambridge University Press 1989
    Google Scholar
  • 5 Collins S D, Lehmann J. Trends and epidemics of influenza and pneumonia: 1918-1951.  Public Health Rep. 1951;  66 1487-1516
    PubMedGoogle Scholar
  • 6 Taubenberger J K, Morens D M. 1918 Influenza: the mother of all pandemics.  Emerg Infect Dis. 2006;  12 15-22
    CrossrefPubMedGoogle Scholar
  • 7 Nuzum J W, Pilot I, Stangl F H, Bonar B E. 1918 pandemic influenza and pneumonia in a large civil hospital.  IMJ Ill Med J. 1976;  150 612-616
    PubMedGoogle Scholar
  • 8 Centers for Disease Control and Prevention . Pandemics Death Toll Since 1900: http://www.pandemicflu.gov/general/
  • 9 Taubenberger J K, Reid A H, Krafft A E, Bijwaard K E, Fanning T G. Initial genetic characterization of the 1918 “Spanish” influenza virus.  Science. 1997;  275 1793-1796
    CrossrefPubMedGoogle Scholar
  • 10 Reid A H, Taubenberger J K, Fanning T G. Evidence of an absence: the genetic origins of the 1918 pandemic influenza virus.  Nat Rev Microbiol. 2004;  2 909-914
    CrossrefPubMedGoogle Scholar
  • 11 Connor R J, Kawaoka Y, Webster R G, Paulson J C. Receptor specificity in human, avian, and equine H2 and H3 influenza virus isolates.  Virology. 1994;  205 17-23
    CrossrefPubMedGoogle Scholar
  • 12 Ito T, Couceiro J N, Kelm S et al.. Molecular basis for the generation in pigs of influenza A viruses with pandemic potential.  J Virol. 1998;  72 7367-7373
    PubMedGoogle Scholar
  • 13 Neumann G, Kawaoka Y. Host range restriction and pathogenicity in the context of influenza pandemic.  Emerg Infect Dis. 2006;  12 881-886
    PubMedGoogle Scholar
  • 14 Hatta M, Gao P, Halfmann P, Kawaoka Y. Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses.  Science. 2001;  293 1840-1842
    CrossrefPubMedGoogle Scholar
  • 15 Webster R G, Geraci J, Petursson G, Skirnisson K. Conjunctivitis in human beings caused by influenza A virus of seals.  N Engl J Med. 1981;  304 911
    PubMedGoogle Scholar
  • 16 Kurtz J, Manvell R J, Banks J. Avian influenza virus isolated from a woman with conjunctivitis.  Lancet. 1996;  348 901-902
    CrossrefPubMedGoogle Scholar
  • 17 Koopmans M, Wilbrink B, Conyn M et al.. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands.  Lancet. 2004;  363 587-593
    CrossrefPubMedGoogle Scholar
  • 18 Tweed S A, Skowronski D M, David S T et al.. Human illness from avian influenza H7N3, British Columbia.  Emerg Infect Dis. 2004;  10 2196-2199
    CrossrefPubMedGoogle Scholar
  • 19 Puzelli S, Di Trani L, Fabiani C et al.. Serological analysis of serum samples from humans exposed to avian H7 influenza viruses in Italy between 1999 and 2003.  J Infect Dis. 2005;  192 1318-1322
    CrossrefPubMedGoogle Scholar
  • 20 Peiris M, Yuen K, Leung C et al.. Human infection with influenza H9N2.  Lancet. 1999;  354 916-917
    CrossrefPubMedGoogle Scholar
  • 21 Guan Y, Shortridge K F, Krauss S, Webster R G. Molecular characterization of H9N2 influenza viruses: were they the donors of the “internal” genes of H5N1 viruses in Hong Kong?.  Proc Natl Acad Sci USA. 1999;  96 9363-9367
    CrossrefPubMedGoogle Scholar
  • 22 Guan Y, Shortridge K F, Krauss S et al.. H9N2 influenza viruses possessing H5N1-like internal genomes continue to circulate in poultry in Southeastern China.  J Virol. 2000;  74 9372-9380
    CrossrefPubMedGoogle Scholar
  • 23 Butt K M, Smith G JD, Chen H et al.. Human infection with an avian H9N2 influenza a virus in Hong Kong in 2003.  J Clin Microbiol. 2005;  43 5760-5767
    CrossrefPubMedGoogle Scholar
  • 24 Subbarao K, Klimov A, Katz J et al.. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness.  Science. 1998;  279 393-396
    CrossrefPubMedGoogle Scholar
  • 25 Shortridge K F, Zhou N N, Guan Y et al.. Characterization of avian H5N1 influenza viruses from poultry in Hong Kong.  Virology. 1998;  252 331-342
    CrossrefPubMedGoogle Scholar
  • 26 Chen H, Smith G J, Zhang S Y et al.. Avian flu: H5N1 virus outbreak in migratory waterfowl.  Nature. 2005;  436 191-192
    PubMedGoogle Scholar
  • 27 World Health Organization .Cumulative Number Of Confirmed Human Cases Of Avian Influenza A/H5N1 Reported to WHO: http://www.who.int/csr/disease/avian_influenza/country/cases_table_2006_08_23/en/index.html
  • 28 Zhu Q Y, Qin E D, Wang N et al.. Fatal infection with influenza A (H5N1) virus in China.  N Engl J Med. 2006;  354 2731-2732
    CrossrefPubMedGoogle Scholar
  • 29 Chan P K. Outbreak of avian influenza A(H5N1) virus infection in Hong Kong in 1997.  Clin Infect Dis. 2002;  34(Suppl 2) S58-S64
    CrossrefPubMedGoogle Scholar
  • 30 Bender C, Hall H, Huang J et al.. Characterization of the surface proteins of influenza A (H5N1) viruses isolated from humans in 1997-1998.  Virology. 1999;  254 115-123
    CrossrefPubMedGoogle Scholar
  • 31 Matrosovich M, Zhou N, Kawaoka Y, Webster R. The surface glycoproteins of H5 influenza viruses isolated from humans, chickens, and wild aquatic birds have distinguishable properties.  J Virol. 1999;  73 1146-1155
    PubMedGoogle Scholar
  • 32 Matrosovich M N, Matrosovich T Y, Gray T, Roberts N A, Klenk H. Human and avian influenza viruses target different cell types in cultures of human airway epithelium.  Proc Natl Acad Sci USA. 2004;  101 4620-4624
    CrossrefPubMedGoogle Scholar
  • 33 Shinya K, Hatta M, Yamada S et al.. Characterization of a human H5N1 influenza A virus isolated in 2003.  J Virol. 2005;  79 9926-9932
    CrossrefPubMedGoogle Scholar
  • 34 Gambaryan A, Tuzikov A, Pazynina G, Bovin N, Balish A, Klimov A. Evolution of the receptor binding phenotype of influenza A (H5) viruses.  Virology. 2006;  344 432-438
    CrossrefPubMedGoogle Scholar
  • 35 World Health Organization Global Influenza Program Surveillance Network . Evolution of H5N1 avian influenza viruses in Asia.  Emerg Infect Dis. 2005;  11 1515-1521
    PubMedGoogle Scholar
  • 36 Liu J, Xiao H, Lei F et al.. Highly pathogenic H5N1 influenza virus infection in migratory birds.  Science. 2005;  309 1206
    CrossrefPubMedGoogle Scholar
  • 37 Cheung C L, Rayner J M, Smith G J et al.. Distribution of amantadine-resistant H5N1 avian influenza variants in Asia.  J Infect Dis. 2006;  193 1626-1629
    CrossrefPubMedGoogle Scholar
  • 38 Epidemiology of WHO-confirmed human cases of avian influenza A(H5N1) infection.  Wkly Epidemiol Rec. 2006;  81 249-257
    PubMedGoogle Scholar
  • 39 The Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5 . Avian influenza A (H5N1) infection in humans.  N Engl J Med. 2005;  353 1374-1385
    CrossrefPubMedGoogle Scholar
  • 40 Keawcharoen J, Oraveerakul K, Kuiken T et al.. Avian influenza H5N1 in tigers and leopards.  Emerg Infect Dis. 2004;  10 2189-2191
    PubMedGoogle Scholar
  • 41 Mounts A W, Kwong H, Izurieta H S et al.. Case-control study of risk factors for avian influenza A (H5N1) disease, Hong Kong, 1997.  J Infect Dis. 1999;  180 505-508
    CrossrefPubMedGoogle Scholar
  • 42 World Health Organization .Review of Latest Available Evidence on Risks to Human Health through Potential Transmission of Avian Influenza (H5N1) through Water and Sewage: http://www.who.int/water_sanitation_health/emerging/h5n1background.pdf
  • 43 Olsen S J, Ungchusak K, Sovann L et al.. Family clustering of avian influenza A (H5N1).  Emerg Infect Dis. 2005;  11 1799-1801
    PubMedGoogle Scholar
  • 44 Ungchusak K, Auewarakul P, Dowell S F et al.. Probable person-to-person transmission of avian influenza A (H5N1).  N Engl J Med. 2005;  352 333-340
    CrossrefPubMedGoogle Scholar
  • 45 de Jong M D, Cam B V, Qui P T et al.. Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma.  N Engl J Med. 2005;  352 686-691
    CrossrefPubMedGoogle Scholar
  • 46 Chotpitayasunondh T, Ungchusak K, Hanshaoworakul W et al.. Human disease from influenza A (H5N1), Thailand, 2004.  Emerg Infect Dis. 2005;  11 201-209
    PubMedGoogle Scholar
  • 47 To K F, Chan P K, Chan K F et al.. Pathology of fatal human infection associated with avian influenza A H5N1 virus.  J Med Virol. 2001;  63 242-246
    CrossrefPubMedGoogle Scholar
  • 48 Govorkova E A, Rehg J E, Krauss S et al.. Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004.  J Virol. 2005;  79 2191-2198
    CrossrefPubMedGoogle Scholar
  • 49 Cheung C, Poon L, Lau A et al.. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease?.  Lancet. 2002;  360 1831-1837
    CrossrefPubMedGoogle Scholar
  • 50 Seo S H, Hoffmann E, Webster R G. The NS1 gene of H5N1 influenza viruses circumvents the host anti-viral cytokine responses.  Virus Res. 2004;  103 107-113
    CrossrefPubMedGoogle Scholar
  • 51 Shinya K, Hamm S, Hatta M, Ito H, Ito T, Kawaoka Y. PB2 amino acid at position 627 affects replicative efficiency, but not cell tropism, of Hong Kong H5N1 influenza A viruses in mice.  Virology. 2004;  320 258-266
    CrossrefPubMedGoogle Scholar
  • 52 Hayden F G, Hay A J. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine.  Curr Top Microbiol Immunol. 1992;  176 119-130
    PubMedGoogle Scholar
  • 53 Cass L M, Efthymiopoulos C, Bye A. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers.  Clin Pharmacokinet. 1999;  36(Suppl 1) 1-11
    PubMedGoogle Scholar
  • 54 Centers for Disease Control and Prevention .Safety and Dose study of Peramavir for Influenza Treatment: http://www.clinicaltrials.gov/ct/show/NCT00297050
  • 55 Leneva I A, Roberts N, Govorkova E A, Goloubeva O G, Webster R G. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses.  Antiviral Res. 2000;  48 101-115
    CrossrefPubMedGoogle Scholar
  • 56 Govorkova E A, Fang H, Tan M, Webster R G. Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells.  Antimicrob Agents Chemother. 2004;  48 4855-4863
    CrossrefPubMedGoogle Scholar
  • 57 Leneva I A, Goloubeva O, Fenton R J, Tisdale M, Webster R G. Efficacy of Zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals.  Antimicrob Agents Chemother. 2001;  45 1216-1224
    CrossrefPubMedGoogle Scholar
  • 58 Tran T H, Nguyen T L, Nguyen T D et al.. Avian influenza A (H5N1) in 10 patients in Vietnam.  N Engl J Med. 2004;  350 1179-1188
    CrossrefPubMedGoogle Scholar
  • 59 World Health Organization .WHO Rapid Advice Guidelines on Pharmacological Management of Humans Infected with Avian Influenza A (H5N1) Virus: http://www.who.int/csr/disease/avian_influenza/guidelines/pharmamanagement/en/index.html
  • 60 Yen H L, Monto A S, Webster R G, Govorkova E A. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice.  J Infect Dis. 2005;  192 665-672
    CrossrefPubMedGoogle Scholar
  • 61 Treanor J J, Hayden F G, Vrooman P S et al.. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial.  JAMA. 2000;  283 1016-1024
    CrossrefPubMedGoogle Scholar
  • 62 Cooper N J, Sutton A J, Abrams K R, Wailoo A, Turner D, Nicholson K G. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials.  BMJ. 2003;  326 1235-1240
    CrossrefPubMedGoogle Scholar
  • 63 de Jong M D, Thanh T T, Khanh T H et al.. Oseltamivir resistance during treatment of influenza A (H5N1) infection.  N Engl J Med. 2005;  353 2667-2672
    CrossrefPubMedGoogle Scholar
  • 64 Le Q M, Kiso M, Someya K et al.. Avian flu: isolation of drug-resistant H5N1 virus.  Nature. 2005;  437 1108
    CrossrefPubMedGoogle Scholar
  • 65 Moscona A. Oseltamivir resistance: disabling our influenza defenses.  N Engl J Med. 2005;  353 2633-2636
    CrossrefPubMedGoogle Scholar
  • 66 Herlocher M L, Truscon R, Elias S et al.. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets.  J Infect Dis. 2004;  190 1627-1630
    CrossrefPubMedGoogle Scholar
  • 67 Ward P, Small I, Smith J, Suter P, Dutkowski R. Oseltamivir (Tamiflu(R)) and its potential for use in the event of an influenza pandemic.  J Antimicrob Chemother. 2005;  55(Suppl 1) 15-21
    PubMedGoogle Scholar
  • 68 Fedson D S. Preparing for pandemic vaccination: an international policy agenda for vaccine development.  J Public Health Policy. 2005;  26 4-29
    CrossrefPubMedGoogle Scholar
  • 69 Katz J M, Lim W, Bridges C B et al.. Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts.  J Infect Dis. 1999;  180 1763-1770
    CrossrefPubMedGoogle Scholar
  • 70 Nicholson K G, Colegate A E, Podda A et al.. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.  Lancet. 2001;  357 1937-1943
    CrossrefPubMedGoogle Scholar
  • 71 Treanor J J, Wilkinson B E, Masseoud F et al.. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans.  Vaccine. 2001;  19 1732-1737
    CrossrefPubMedGoogle Scholar
  • 72 Treanor J J, Campbell J D, Zangwill K M, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.  N Engl J Med. 2006;  354 1343-1351
    CrossrefPubMedGoogle Scholar
  • 73 Bresson J L, Perronne C, Launay O et al.. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.  Lancet. 2006;  367 1657-1664
    CrossrefPubMedGoogle Scholar
  • 74 Lin J, Zhang J, Dong X et al.. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.  Lancet. 2006;  368 991-997
    CrossrefPubMedGoogle Scholar
  • 75 GSK press release. GSK Reports Significant Advance in H5N1 Pandemic Flu Vaccine Programme: http://www.gsk.com/ControllerServlet?appId=4&pageId=402&newsid=868
    Google Scholar
  • 76 Stephenson I, Nicholson K G, Colegate A et al.. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population.  Vaccine. 2003;  21 1687-1693
    CrossrefPubMedGoogle Scholar
  • 77 Belshe R B, Mendelman P M, Treanor J et al.. The efficacy of live attenuated, cold-adapted, trivalent, intranasal Influenzavirus vaccine in children.  N Engl J Med. 1998;  338 1405-1412
    CrossrefPubMedGoogle Scholar
  • 78 Belshe R B, Gruber W C, Mendelman P M et al.. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine.  J Pediatr. 2000;  136 168-175
    CrossrefPubMedGoogle Scholar
  • 79 National Strategy for Pandemic Influenza: http://www.whitehouse.gov/homeland/pandemic-influenza.html
  • 80 Yuen K Y, Chan P K, Peiris M et al.. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus.  Lancet. 1998;  351 467-471
    CrossrefPubMedGoogle Scholar
  • 81 Peiris J, Yu W C, Leung C W et al.. Re-emergence of fatal human influenza A subtype H5N1 disease.  Lancet. 2004;  363 617-619
    CrossrefPubMedGoogle Scholar
  • 82 Tamura D, Miura T, Kikuchi Y. Oseltamivir phosphate in infants under 1 year of age with influenza infection.  Pediatr Int. 2005;  47 484
    CrossrefPubMedGoogle Scholar

Sumanth RajagopalM.D. 

Department of Medicine, Infectious Diseases Division, University of Rochester School of Medicine and Dentistry

601 Elmwood Ave., Rochester, NY 14642

Email: sumanth_rajagopal@urmc.rochester.edu

      >